Get the Stockscreener App
81.55
4.06%
-3.45
Inhibrx Biosciences Inc stock is traded at $81.55, with a volume of 164.73K.
It is down -4.06% in the last 24 hours and down -14.28% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$85.00
Open:
$86
24h Volume:
164.73K
Relative Volume:
0.37
Market Cap:
$1.20B
Revenue:
$1.30M
Net Income/Loss:
$-130.19M
P/E Ratio:
-9.7201
EPS:
-8.3898
Net Cash Flow:
$-131.94M
1W Performance:
-6.68%
1M Performance:
-14.28%
6M Performance:
+9.23%
1Y Performance:
+253.49%
1-Day Range:
$81.54
$86.00
1-Week Range:
$81.54
$90.00
52-Week Range:
$20.55
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
81.55 | 1.20B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
INBX|Inhibrx Biosciences Inc|Price:81.550|Chg%:-3.450 - TradingKey
Price-Driven Insight from (INBX) for Rule-Based Strategy - Stock Traders Daily
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX) - Seeking Alpha
Inhibrx Biosciences Expands Credit Facility to $500 Million - TipRanks
Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million - Bitget
Inhibrx Biosciences Secures $500 Million Credit Facility with Oxford Finance to Accelerate Clinical Pipeline Expansion - Minichart
Inhibrx expands credit facility to $500 million with Oxford By Investing.com - Investing.com South Africa
Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants - TradingView
Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit - Stock Titan
Inhibrx Shares Fall After Expanding Loan Agreement to $500M - Moomoo
Inhibrx expands credit facility to $500 million with Oxford - Investing.com
Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million - Moomoo
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history - Bitget
Are you looking for a top momentum pick? Why Inhibrx Biosciences, Inc. (INBX) is a great choice - MSN
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice - Yahoo Finance
Top Cybin (HELP) Competitors 2026 - MarketBeat
INBX Q1 2026 Earnings: Wider-than-Expected Loss Despite Modest Stock GainEarnings Growth Analysis - dars.gov.et
Inhibrx Biosciences (INBX) Stock Analysis Report | Financials & Insights - Benzinga España
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors - simplywall.st
(INBX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2500 Growth Benchmark - marketscreener.com
INBX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Company Reports No Revenue - dars.gov.et
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2000 Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell Microcap Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In? - Sahm
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Enterprise value to revenue forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
Price to sales forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
INBX News | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Inhibrx Biosciences urges continued research to address unmet needs in rare cancer treatment - Traders Union
Inhibrx Biosciences, Inc. Actuals & Estimates (NASDAQ:INBX) - TradingView
INBX Forecast — Price Target — Prediction for 2027 - TradingView
Inhibrx Biosciences Inc (INBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More - RTTNews
The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart - Sahm
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
INBX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline AdvancesEarnings Sentiment Score - dars.gov.et
INBX Q1 2026 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentCapex Guidance - DonanımHaber
(INBX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Inhibrx Biosciences (INBX) Stock Near Analyst Target After FDA Filing for Ozekibart - Sahm
Inhibrx Biosciences Inc (INBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences Inc (INBX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibrx Biosciences Inc (INBX) Institutional Confidence - TradingKey
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inhibrx Biosciences Inc (INBX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com - Investing.com Australia
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):